View Older Stories
-
Zoetis (ZTS) Declares $0.53 Quarterly Dividend; 2.7% Yield
-
Burry adds to beaten-down stocks, buys Lululemon, warns of AI bubble
-
Burry says he added to MercadoLibre, Zoetis positions
-
Burry adds to MercadoLibre, Zoetis positions
-
Zoetis Inc. (ZTS) PT Lowered to $105 at Stifel
-
Zoetis (ZTS) Misses Q1 EPS by 9c; offers guidance
-
Citi Opens 90-Day Upside Catalyst Watch on Zoetis Inc. (ZTS)
-
Jefferies Upgrades The Simply Goods Group (SMPL) to Buy, 'Well-known Pressures, but Valuation is Punitive'
-
Leerink Partners Reiterates Market Perform Rating on Zoetis Inc. (ZTS) following management meeting
-
Nephron Downgrades Zoetis Inc. (ZTS) to Hold
-
William Blair Reiterates Outperform Rating on Zoetis Inc. (ZTS) after announcing accusation of Neogen's genomics business
-
BTIG Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Morgan Stanley on Zoetis Inc. (ZTS): 'Pre-Call View – Shares Should Rise; Valuation Compelling'
-
Jefferies on Zoetis Inc. (ZTS): 'Solid end to a volatile year'
-
Zoetis (ZTS) Tops Q4 EPS by 8c; offers guidance
-
Zoetis (ZTS) Declares $0.53 Quarterly Dividend; 1.7% Yield
-
Piper Sandler Downgrades Zoetis Inc. (ZTS) to Neutral
-
BofA Securities Downgrades Zoetis Inc. (ZTS) to Neutral
-
Zoetis (ZTS) Raises Quarterly Dividend 6% to $0.53; 1.8% Yield
-
Zoetis gains Health Canada approval for cat arthritis pain treatment
-
BTIG: 'we think ZTS is well-positioned to execute in an attractive global animal health market'
-
Zoetis gets European approval for dog arthritis pain treatment
-
KeyBanc Starts Zoetis Inc. (ZTS) at Sector Weight
-
Zoetis (ZTS) PT Lowered to $130 at Stifel: 'Street's 2026 GM May Be Too High'
-
Zoetis Inc. (ZTS) PT Lowered to $160 at BTIG
-
Increasing unusual call option volume: BHVN BW RPD SLG PRMB APPS QURE ZTS
-
Zoetis Inc. (ZTS) PT Lowered to $130 at Leerink Partners
-
Zoetis (ZTS) Tops Q3 EPS by 8c; cuts revenue guidance
-
Zoetis gets European approval for cat arthritis pain drug Portela
-
Zoetis receives Health Canada approval for dog arthritis pain therapy
-
Zoetis gets positive opinion for dog osteoarthritis pain treatment
-
Zoetis (ZTS) Declares $0.50 Quarterly Dividend; 1.4% Yield
-
Zoetis gets FDA conditional approval for cattle screwworm treatment
-
FDA grants conditional approval for Dectomax-CA1 to treat screwworm in cattle
-
Zoetis gets positive opinion for cat arthritis pain treatment
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Zoetis Inc. (ZTS) PT Lowered to $165 at UBS
-
Zoetis (ZTS) Files Mixed Shelf
-
Zoetis (ZTS) Tops Q2 EPS by 14c' offers guidance
-
Leerink Partners Downgrades Zoetis Inc. (ZTS) to Market Perform
-
UBS Reiterates Neutral Rating on Zoetis Inc. (ZTS)
-
Piper Sandler Reiterates Overweight Rating on Zoetis Inc. (ZTS)
-
Stifel Downgrades Zoetis Inc. (ZTS) to Hold
-
Zoetis (ZTS): Dr. Mark Stetter Elected to Zoetis Board of Directors
-
BTIG Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Zoetis Inc. (ZTS) PT Raised to $210 at Piper Sandler
-
Zoetis Inc. (ZTS) PT Lowered to $170 at UBS
-
Zoetis Inc. (ZTS) PT Lowered to $180 at Leerink Partners
-
Zoetis (ZTS) Tops Q1 EPS by 7c; offers guidance
-
Amazon (AMZN) Comments Circulate

